Company (Country/Symbol)

Company (Country/Symbol)

Type/Product Area

Terms/Details (Month)

Abgenix Inc. (ABGX)

Gliatech Inc. (GLIA)

License and option agreement/use of Abgenix's XenoMouse technology to generate fully human monoclonal antibodies to the complement protein properdin for use in the fields of cardiovascular and inflammatory diseases

Abgenix will receive a technology access payment and could receive additional fees and milestones, plus royalties on product sales; Gliatech will be responsible for development, manufacturing and marketing (1/00)

Abgenix Inc. (ABGX)

Neuralab Ltd. (subsidiary of Elan Corp. plc [Ireland; NYSE: ELN)

License and option agreement/use of Abgenix's XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of neurological diseases

Abgenix will receive a technology access payment and could receive additional fees and milestones, plus royaltieson product sales; Elan will be responsible for development, manufacturing and marketing (1/00)

Actelion Ltd.* (Switzerland)

Genentech Inc. (NYSE:DNA)

Development and marketing/Tezosentan; endothelin receptor antagonist

The companies will co-promote tezosentan upon FDA approval; Actelion wil lead the development effort, while Genentech will lead commercialization; Genentech will pay Actelion an up-front fee of $15M along with additional milestone payments; Genentech will make an equity investment in Actelion's upcoming initial public offering (2/00)

Affymetrix Inc. (AFFX)

NEN Life Science Products*

License agreement/low- and medium-density DNA arrays

NEN has been granted a non-exclusive, worldwide, royalty-bearing licenseallowing it to manufacture, use and sell low- and medium-density pre-spotted arrays; the license applies only to the research field for gene expression analysis and comparative genomic hybridization with mechanically-spotted arrays; Affymetrix will receive undisclosed fees and royalty payments on products sold by NEN; NEN will cooperatively promote Affymetrix' scanners and software (3/00)

AeroGen Inc.*

PathoGenesis Corp. (PGNS)

Research collaboration/use of PathoGenesis' FDA-approved TOBI (tobramycin solution for inhalation) and AeroGen's handheld, portable AeroDose Inhaler; goal is to reduce drug's delivery time from 15-20 minutes to 5-10 minutes or less

Under a development and supply agreement, PathoGenesis will reimburse AeroGen for costs incurred in developing the inhaler and will obtain worldwide exclusive distribution rights; AeroGen will receive royalties on all sales; under a separate agreement, PathoGenesis will invest $2.5M in AeroGen's convertible preferred stock (3/00)

Allergan (NYSE:AGN)

Dura Pharmaceuticals Inc. (DURA)

Commercialization/selected Allergan products in the U.S. primary care and respiratory segments

The companies entered a multi-year, multi-product agreement under which they will co-launch Alocril, Allergan's proprietary topical compound for the treatment of itch associated withallergic conjunctivitis; Allergan will promote Alocril to ophthalmologists, and Dura will promote it to primary care practitioners and respiratory specialists; the agreement includes a joint structure to evaluate additional opportunities for Dura to promote specific development-stage products, once they receive approval, and a commitment to launch a second product to the same segments on an unspecified date (2/00)

Amersham Pharmacia Biotech (UK; LSE:NAM)

Analytica of Branford*

Marketing/mass spectrometry systems for protein analysis

The companies will collaborate in the development of new, leading-edge systems for the characterization of proteins and peptides; the terms of the agreement are for exclusive distribution and manufacturing of the systems by Amersham; Amersham intends to acquire a majority stake in Analytica (3/00)

Amphioxus Cell Technologies Inc.*

Incyte Genomics (INCY)

License agreement/Amphioxus' C3A cloned human liver cell line for the creation of gene-expression databases

Incyte gains exclusive access to the cell line for creation of gene-expression databases; companies also have a co-marketing arrangement for distribution and licensing of the cell line (1/00)

Amrad Corp. Ltd. (Australia; ASX:AML)

DevCo Pharmaceuticals* (UK)

License agreement/Amrad's AM36 compound as a treatment for stroke

DevCo will design, carry out and fund the development program up to and including proof-of-principle Phase II studies, at which point Amrad has the right of first refusal to either buy back worldwide rights or share in commercial proceeds; Amrad retains rights to market the drug in Australia and New Zealand (3/00)

AndroSolutions Inc.*

Vivus Inc. (VVUS)

Joint venture/intellectual property related to female sexual dysfunction

Companies formed Asivi LLC, in which Vivus placed its U.S. female sexual dysfunction patent and European application, and AndroSolutions placed its U.S. and European applications; Asivi gives Vivus exclusive worldwide rights to commercialize the technologies in return for milestones and royalties (3/00)

Applied Molecular Evolution Inc.*

Bio-Management Inc.*

Development/DirectAME directed evolution technology for the development of antibodies for therapeutic and diagnostic applications

BMI will fund research covering two to four antibodies, as well as make milestone payments of up to $17M; AME also will receive royalties on marketed products developed with its DirectAME technology (2/00)

Aquila Biopharmaceuticals Inc. (AQLA)

Neuralab Ltd. (wholly owned subsidiary of Elan Corp. plc [Ireland; NYSE:ELN])

License agreement/use of Aquila's Stimulon adjuvant QS-21 with an undisclosed antigen in the field of Alzheimer's disease

Aquila received a license payment and could receive additional fees and milestones plus royalties on product sales; Elan will be responsible for product development and marketing; companies also signed a supply agreement for the adjuvant (1/00)

Athersys Inc.*

Elan Corp. plc (Ireland; NYSE: ELN)

Development and marketing/undisclosed therapeutic protein for the treatment of AIDS-associated muscle wasting

The companies will combine Athersys' RAGE (Random Activation of Gene Expression) technology with Elan's Medipad drug delivery system; Elan has made a significant equity investment in Athersys; further details ND (2/00)

Atugen AG* (Germany)

Axys Pharmaceuticals Inc. (AXPH)

Research collaboration/gene target validation services through Atugen's U.S. subsidiary

Axys will provide Atugen with gene targets in oncology, and Atugen will develop GeneBloc reagents to knock down the genes of interest to evaluate gene function and potential as therapeutic drug targets; Atugen will perform quantitative RNA analysis and technology transfer to enable Axys to use the best GeneBlocs; financial details ND (3/00)

Atugen AG* (Germany)

GPC AG* (Germany)

Technology alliance/companies will combine technologies to create a fully integrated functional genomics and proteomics platform

Companies will offer combined platform to third parties for target discovery and validation (2/00)

Aurora Biosciences Corp. (ABSC)

Rigel Inc.*

Reciprocal technology access/Aurora's green fluorescent protein technology and Rigel's retroviral and peptide selection technologies

Rigel gains a non-exclusive license to use Aurora's GFP technology in certain areas related to gene analysis; Aurora will receive an up-front payment, annual fees and equity in Rigel; Rigel will permit Aurora to access combinatorial screening technology for target identification and validation; both companies can perform services for third parties in exchange for royalties on the services and downstream revenues (2/00)

AutoImmune Inc. (AIMM)

Elan Corp. plc (Ireland; NYSE: ELN)

Patent purchase/undisclosed therapeutic for Alzheimer's disease

The companies entered an agreement whereby a subsidiary of Elan Corp. has purchased all of AutoImmune's rights to certain patent applications involving the treatment of Alzheimer's disease; AutoImmune will receive up to $7M in cash in a combination of up-front fees and contingent payments over the next three years; at the time the contingent payments are made, the buyer will receive warrants to purchase up to 750,000 shares of AutoImmune stock at the market price for AutoImmune shares when the warrants are issued (3/00)

AVI BioPharma


Clinical trial collaboration/AVI's Resten-NG, a gene-targeted therapeutic for cardiovascular restenosis

IVT will supply its Infiltrator intramural delivery catheters for upcoming Phase II trials; AVI will use the catheter in its Resten-NG development program; further details ND (3/00)

Avigen Inc. (AVGN)

BTG International Ltd. (subsidiary of BTG plc [UK;LSE:BGC])

License/Factor IX gene patents

Avigen obtained a non-exclusive, worldwide license to Factor IX gene patents; Avigen has the right to make, use, sell, offer for sale, or import viral vector systems, including adeno-associated virus, using the Factor IX gene for in vivo human gene therapy; Avigen also has the right to sublicense the patents to third parties; financial details ND (3/00)

Axys Pharmaceuticals Inc. (AXPH)

Cytovia Inc.*

Development/anticancer agents that induce apoptosis; the collaboration will leverage Axys' 700,000-compound chemical library and its medicinal chemistry, preclinical and clinical development strengths with Cytovia's high-through-put screening technologies and molecular and cellularbiologies

Each company will fund its own research; Axys will make an up-front equity investment in Cytovia, and will have first rights to develop and commercialize any drug candidates that result from the collaborative research, and will pay Cytovia a royalty on product sales; Cytoiva may exercise a profit share option at a predetermined point during development in lieu of royalties; if Axys does not choose to develop a drug candidate, Cytovia will have the right to do so with Axys having the right to either a profit share option or a royalty on sales (3/00)

Biohybrid Inc.*

TKB Associates*

Access/CD8-mediated veto

Biohybrid purchased the patent rights to CD8-mediated veto from TKB; TKB will receive an equity position in the company, as well as royalty and milestone payments; further details ND (3/00)

Bioject Medical Technologies Inc. (BJCT)

Amgen Inc. (AMGN)

Development collaboration/use of Bioject's needle-free jet injection system to deliver Amgen products

Amgen will invest $1.5M in Bioject's common stock and up to $3.1M in future milestones, fees and development support; Amgen receives an exclusive license to the technology for delivery of Amgen products for two indications; Amgen also gains an option to further license the technology for other Amgen products; agreement outlines a future commercial supply agreement (3/00)

Biovector Therapeutics*

BioChem Pharma (Canada; BCHE)

Development/nasal vaccine against Streptococcus pneumoniae

The companies initiated the development process of a nasal vaccine against S. pneumoniae incorporating Biovector's proprietary drug delivery technology and BioChem's proprietary protein antigen; activities between the two companies will be coordinated at BioChem's vaccine development center in Northborough, Mass.; further details ND (2/00)

Cadus Pharmaceutical Corp. (KDUS)

OSI Pharmaceuticals Inc. (OSIP)

License/G protein-coupled receptor technologies

OSI received a non-exclusive license to Cadus's yeast G protein-coupled receptor technologies, includingvarious reagents, a library of over 30,000 yeast strains and proprietary bioinformatics software; financial details ND (2/00)

Cambridge Antibody Technologies plc (LSE:CAT)

Human Genome Sciences Inc. (HGSI)

Research collaboration/use of CAT's technology to develop an unlimited number of fully human antibodies for therapeutic and diagnostic purposes

Ten-year agreement providing HGS with rights to use CAT technology to develop and sell human antibodies, including research applications; CAT has the right to select up to 24 HGS antigens for preclinical development, with HGS retaining the option to share clinical development costs and share profits equally on up to 18 such products; HGS will buy 1.67M shares of CAT for the $55M, a 20% premium; HGS also will pay $12M in licensing fees, including research support; HGS will pay milestones and royalties on products it develops (2/00)

Cambridge NeuroScience Inc. (OTC BB:CNSI)

Algos Pharmaceutical Corp. (ALGO)

License agreement/Algos patents related to pain products

Cambridge has been granted a paid-up license under three Algos patents to develop products for the treatment of pain; Algosreceives the right to negotiate to develop and/or commercialize these products (1/00)

Cell Genesys Inc. (CEGE)

Clontech Laboratories Inc. (a subsidiary of Becton Dickinson & Co.; NYSE:BDX)

License/retroviral gene delivery technology

Cell Genesys licensed certain retroviral gene delivery technology to Clontech; Cell Genesys will receive royalties on worldwide sales of research kits developed as a result of the collaboration, and on any future products employing its gene delivery technology; customers of Clontech who intend to market products arising from research using these kits will be required to obtain an additonal license to the technology from Cell Genesys prior to product comercialization; financial details ND (1/00)

CeNeS Pharmaceuticals plc* (UK)

Bioglan Pharma plc (UK; LSE:BGP)

License and development agreement/use of Bioglan's aerosol technology to develop self-administered formulation of opiate analgesic

When CeNeS joins the Official List, Bioglan will buy 1M ordinary shares for #1M (US $1.6M), and has an option for an additional #2M (US$3.2M) worth in 2003; CeNeS gains exclusive rights to market the product in the European Union, and Bioglan has rights for the rest of the world; CeNeS will pay a license fee and royalties to Bioglan, which will run the development program; companies plan to enter an additional agreement under which Bioglan will supply the product to CeNeS (2/00)

Cetek Corp.*

Cubist Pharmaceuticals

Research collaboration/Cetek will develop capillary electrophoresis assays for a Cubist target and will screen the assays against Cubist's compound libraries

Formal agreement follows pilot study (1/00)

Chronix Biomedical*

Hemispherx Biopharma Inc.(AMEX:HEB)

Research collaboration/Chronix's gene reshuffling technology; marketing of plasma RNA test that measures reshuffled genes (research use only) and use of Hemispherx's chronic fatigue syndrome database to identify gene sequences of relevance to CFS, Gulf War Syndrome and related chronic diseases

Companies jointly will develop intellectual property on new products for diagnosing the various stages of gene reshuffling; Hemispherix will assist in marketing Chronix's plasma RNA test and will take an equity stake in Chronix (3/00)

Clear Solutions Biotech*

Laboratorios Sophia* (Mexico)

Research collaboration/use of Clear Solutions' hydrazide mediated cross-linking technology to link therapeutic genes to high-molecular weight hyaluronic acid, allowing for sustained delivery of genes to the eye for the treatment of dry eye syndrome

Collaboration will be conducted with University of Guadalajara and with support of the federal government of Mexico (3/00)

Cognetix Inc.*

Elan Corp. plc (Ireland; NYSE: ELN)

License agreement and research collaboration/development and commercialization of Cognetix's contulakin-G (CGX-1160) for short-term management of post-operative pain using Elan's Medipad drug delivery system

Cognetix and Elan will license relevant technologies to a Cognetix subsidiary; Elan has made an equity investment in Cognetix and will support costs associated with the project (2/00)

Compugen Ltd.* (Israel)

Human Genome Sciences Inc. (HGSI)

Research collaboration/use of Compugen's LEADS computational analysis platform to analyze HGSI's collection of genes and create a chromosomal map of most expressed genes, a large collection of single nucleotide polymorphisms in expressed genes, and a comprehensive description of human gene organization and splicing variants

HGSI will pay Compugen a fixed multimillion-dollar fee for work to be completed within 12 months, and will hold the exclusive rights to commercialize the results of the study (3/00)

Corixa Corp. (CRXA)

QLT PhotoTherapeutics Inc. (Canada; QLTI)

Research collaboration/QLT will evaluate Corixa immunotherapeutic compounds in combination withphotodynamic therapy

QLT will pay a fee for the exclusive right to use certain compounds for certain diseases, which QLT will evaluate in combination with photodynamic therapy; if successful, QLT's continued development of the Corixa technology would call for the generation of additional product candidates by Corixa in exchange for additional licensing fees and royalties, and the potential purchase by QLT of a small amount of equity in Corixa at a premium (3/00)

CytoTherapeutics Inc. (CTII)

Neurotech SA* (France)

Technology sale/CytoTherapeutics' Encapsulated Cell Technology

CytoTherapeutics will receive an initial payment of $3M, royalties on future product sales, and a portion of Neurotech revenues from third parties, in return for the assignment to Neurotech of intellectual property rights related to Encapsulated Cell Technology; in addition, CytoTherapeutics retains nonexclusive rights to use the technology in combination with stem-cell technology, and in the field of vaccines for infectious diseases (1/00)

DepoMed Inc. (AMEX:DMI)

Elan Corp. plc (Ireland; NYSE: ELN)

Joint venture/development of gastric retention oral drug delivery technologies and products using those technologies

Companies completed previously announced (12/99) agreement, creating DepoMed Development Ltd.; both JV partners will provide clinical development, regulatory and business guidance; Elan will make a $5M common-stock investment in DepoMed at $7 per share; DepoMed initially will own 80.1% of the JV while Elan retains the right to acquire up to 50% ownership; companies estimate program will require about $10M, with each contributing funding in proportion to its respective share ownership interests (1/00)

Diaclone SA (wholly owned subsidiary of the Biotest Group; France)

Nexell Therapeutics Inc. (NEXL)

License agreements/access to seven Diaclone monoclonal antibodies for ex vivo cell therapy using Nexell's Isolex cell selection system

Companies signed two agreements, one of which grants Nexell an exclusive license to Diaclone's CD2 antibody for targeting T cells; the second agreement provides access to six additional antibodies, including CD138 (useful for purging myeloma cells), CD25 (a T-cell activation marker), CD56 and CD16 (markers for natural killer cells), CD14 (a monocyte marker), and CD4 (the marker for T-helper cells) (1/00)

DNX Transgenic Sciences (subsidiary of Phoenix International Life Sciences [Canada; PHXI])

CuraGen Corp. (CRGN)

Research collaboration/DNX will develop transgenic mice based upon a large number of CuraGen gene constructs; CuraGen will use the mice to identify novel therapeutic proteins

Three-year agreement under which CuraGen will fund development and characterization of transgenic mice from at least 45 gene constructs; DNX and CuraGen jointly will genotype, select and characterize more than 135 transgenic mouse lines in a flexible collaborative research program; research will take place at DNX's facilities (1/00)

Edenland Inc.*

Hollis-Eden Pharmaceuticals Inc. (HEPH)

License agreement and research collaboration/technology that covers Hollis-Eden's lead HIV compound, HE2000

Hollis-Eden reached a settlement on pending arbitration issues with Patrick Pendergast, chairman of Colthurst Ltd. and Edenland; parties replaced original Colthurst license agreement with a new agreement in which all patents, patent applications and potential improvements of the Colthurst technology will be irrevocably assigned to Hollis-Eden on a royalty-free basis in exchange for equity in Hollis-Eden; parties also entered a sponsored research agreement under which Edenland will license to Hollis-Eden a number of compounds and related patents and applications, and Hollis-Eden will fund additional preclinical research projects at Edenland, with licensing rights (and royalty obligations) for the results of the research (1/00)

Emisphere Technologies Inc. (EMIS)

Regeneron Pharmaceuticals Inc. (REGN)

Research collaboration/use of Emisphere's oral drug delivery technology for Regeneron's protein product candidate Axokine, which is in clinical trials for obesity

Emisphere could receive fees, research funding and milestones totaling $31M; Emisphere also will receive royalties; Regeneron has exclusive worldwide commercialization rights (3/00)

Eos Biotechnology*

Medarex Inc. (MEDX)

Research collaboration/use of Medarex's HuMAb Mouse technology to create fully human antibodies to Eos targets associated with cancer and other diseases

Medarex will provide Eos up to $25M in cash, consisting of an initial payment of $5M and an additional $20M in milestones; Medarex also will provide Eos with credits against future milestones and royalties totaling $75M that would otherwise be payable in connection with Eos' use of HuMAb Mouse technology over a multi-year period; Eos will develop six to nine products through Phase IIa, at which point they will be subject to joint ownership with Medarex; Medarex will have the option to obtain exclusive marketing rights in Europe for some of those products and may be retained by the alliance to perform GMP manufacturing services (2/00)

Etiogen Pharmaceuticals Inc.*

Pathobiotek Diagnostics Inc. (PBTK)

Development collaboration/development of products for an activating virus discovered by Pathobiotek with potential applications in cancer diagnostics and therapeutics; Etiogen will work with Pathobiotek to complete the sequencing of the virus

Companies signed letter of intent for collabboration; products that will be licensed to third parties for marketing and distribution; diagnostic products are expected to be available by the end of 2000 (1/00)

Evotec BioSystems AG (Germany; Neuer Markt: EVT)

Sugen Inc. (wholly owned subsidiary of Pharmacia & Upjohn; NYSE:PNU)

Research collaboration/discovery and development of small-molecule drugs that target specific cellular transduction pathways; Evotec initially will screen Sugen phosphatase targets against Sugen compound libraries with the aim of finding inhibitors

Evotec receives an up-front payment, a milestone payment upon completion of the first target screen and a final payment at the end of the collaboration; Sugen retains exclusive worldwide rights to commercialize products, while Evotec will be entitled to royalties on sales (3/00)

Gemini Holdings plc* (UK)

Lineage Biomedical Inc.* (Canada)

Joint venture/identification of genes for common diseases using the population resources of Newfoundland and Labrador, where certain diseases (including psoriasis, rheumatoid arthritis and diabetes) are more prevalent

Companies created Newfoundland Genomics and will establish a research facility in Newfoundland and Labrador to identify disease-causing genes; any DNA collected in the province will remain in Newfoundland and Labrador; Gemini will provide a limited license to its genetic, computing, bioinformatic and scientific expertise, as well as funding some operating costs (2/00)

Genome Therapeutics Corp. (GENE)

ICAgen Inc.*

Research collaboration/pharmacogenomics; use of Genome Therapeutics' polymorphism detection platform to analyze genetic variations that could aid in the design of clinical trials for an ICAgen ion channel target

Genome Therapeutics will seek to identify efficacy-related polymorphisms using its collection of DNA samples from various ethnic groups (2/00)

Genzyme Molecular Oncology (GZMO)

CompugenLtd.* (Israel)

Database collaboration/integration of GMO's SAGE gene expression database into Compugen's site and use of the database with Compugen's LEADS platform

Companies signed two separate agreements under which they will share revenues related to the SAGE database; under the first agreement, companies will share revenue generated by customer use of SAGE on Compugen's website; under second agreement, the SAGE database will be integrated into Compugen's LEADS platform, providing potential royalties to GMO on sales of the platform (1/00)

Genzyme Transgenics Corp. (GZTC)

Progenics Pharmaceuticals Inc. (PGNX)

Research collaboration/development of a transgenic source of supply for Progenics' PRO 542 anti-HIV

Expanded agreement based on successful feasibility studies; Genzyme Transgenics will develop transgenic goats that produce PRO 542 in their milk in exchange for fees and milestones; Genzyme Transgenics will supply clinical trial materials, and the agreement contemplates eventual commercial supply (2/00)

GyneLogix Inc.*

The Medicines Company*

License agreement/GyneLogix's CTV-05, a strain of human Lactobacillus with applications in urogenital and reproductive health; initial indication is for treatment of bacterial vaginosis

Medicines gains exclusive worldwide rights (1/00)

Human Genome Sciences Inc. (HGSI)

Vical Inc. (VICL)

Reciprocal license agreement/use of HGS' genes and Vical's naked DNA gene delivery technology

Companies entered reciprocal royalty-bearing license under which Vical has the option to exclusively license up to three genes from the HGS database for gene-based product development; HGS has the option to license Vical's naked DNA gene delivery technology for use in up to three gene-based products; in a related deal (see below), Vascular Genetics Inc. licensed Vical's delivery technology (2/00)

Idun Pharmaceuticals*

Elan Corp. plc (Ireland; NYSE: ELN)

Research collaboration/development of compounds for treating stroke

Companies completed negotiations to form a wholly owned subsidiary of Idun that will focus on the stroke program; within subsidiary, companies will collaborate on continuing the development of a series of drug candidates licensed from both parties that have demonstrated activity in animal models (2/00)

Incyte Genomics (INCY)

Biogen Inc. (BGEN)

Database access/Incyte's LifeSeq Gold gene database and LifeTools data management software

Incyte could receive milestones and royalties on sales of products developed with its technology and database information (1/00)

Incyte Genomics (INCY)

Corixa Corp. (CRXA)

Database acces/Incyte's LifeSeq Gold gene database for use in Corixa's efforts to develop vaccines, monoclonal antibodies and diagnostics

Incyte could receive milestones and royalties on products developed using the Incyte technology and information (2/00)

Incyte Genomics (INCY)

Vertex Pharmaceuticals Inc. (VRTX)

Database access/Incyte's LifeSeq Gold gene database for use in small-molecule drug discovery

Incyte could receive future milestones and royalties on products developed using the Incyte technology and information (2/00)

Isis Pharmaceuticals Inc. (ISIP)

Elan Corp. plc (Ireland; NYSE: ELN)

Development collaboration/ISIS 14803, a clinical-stage antisense drug that inhibits hepatitis C virus replication

Companies signed a binding letter of agreement to create a new subsidiary of Isis for development of the drug; Elan will purchase $7.5M of Isis common stock in 1Q:00 and possibly an additional $7.5M as a milestone; both tranches are at a premium to market price; Elan also will purchase convertible preferred stock in Isis and will make available a $12M line of credit for Isis' funding commitment to the subsidiary (1/00)

Medarex Inc. (MEDX)

Regeneron Pharmaceuticals Inc. (REGN)

Research collaboration/use of Medarex's HuMAb Mouse technology to create fully human antibodies to targets identified by Regeneron, including growth factors, cytokines and receptors

The companies have selected more than 20 initial targets and plan to add more in the future; they will share preclinical and clinical responsibilities and will jointly market any resulting products (3/00)

Microbiotix Inc.*

BioChem Pharma Inc. (Canada; BCHE)

Research collaboration/identification and development of inhibitors of enzymes that are essential for bacterial DNA replication; goal is to create new antibiotics for resistant organisms

Three-year collaboration under which BioChem will contribute research funding and personnel, and also will take an equity stake in Microbiotix; BioChem also may pay milestones and royalties on resulting products (2/00)

Molecular Applications Group*

Structural Bioinformatics Inc.*

Bioinformatics purchase/MAG's GeneMine technology for enhancement of SBI's protein structural databases

Purchase agreement (1/00)

Nanoscale Combinatorial Synthesis Inc.*

Euroscreen SA* (Belgium)

Research collaboration/use of Nanoscale's small-molecule libraries with Euroscreen's collection of cloned G protein-coupled receptors

Terms include access to Nanoscale's capabilities in follow-up synthesis and lead optimization (1/00)

Oxford BioMedica plc

Immuno-Designed Molecules SA*

Research collaboration/development of anticancer cell therapy products incorporating Oxford's immunecell genetic engineering technology and IDM's technology for manipulating individual patients' immune cells

Oxford and IDM jointly will develop and share revenues from therapeutics (1/00)

Paracel Inc.*

Tularik Inc. (TLRK)

Equipment installation/Paracel's GeneMatcher genetic data analysis system

Paracel installed the system at Tularik (2/00)

PathoGenesis Corp. (PGNS)

Chiron Corp. (CHIR)

Research collaboration/development of new antibiotics through use of PathoGenesis' expertise in bacterial target discovery and antibiotic development, along with Chiron's combinatorial chemistry library and screening expertise

Work is funded in part by PathoGenesis' $1.4M grant from the Cystic Fibrosis Foundation (1/00)

Pharmacopeia Inc. (PCOP)

Progenics Pharmaceuticals Inc. (PGNX)

Research collaboration/discovery of small-molecule HIV therapeutics, focusing on compounds that block attachment of the virus to CD4

Progenics will provide technologies and expertise related to the interaction between HIV and CD4, and Pharmacopeia will provide its lead discovery services, including high-throughput screening of its internal compound library; Progenics will obtain exclusive licenses to all active compounds identified; Pharmacopeia will receive fees for screening services, as well as milestones and royalties on resulting products (3/00)

PPD Discovery (wholly owned subsidiary of PPD Inc.; PPDI)

Agouron Pharmaceuticals (wholly owned subsidiary of Warner-LambertCo.; NYSE:WLA)

Research collaboration/use of PPD Discovery's functional genomics system to identify human genes required for the replication of HIV

Agouron will provide an up-front payment and a technology access fee, as well as support research at PPD Discovery's genomics facility; PPD Discovery will receive R&D milestones and royalties on sales of resulting products; PPD Discovery retains rights to pharmacogenomic and diagnostic applications and products, and also may develop therapeutics that Agouronwill have an option to license; Agouron will receive royalties on PPD Discovery diagnostic and pharmacogenomic products resulting from the collaboration (2/00)

Praecis Pharmaceuticals Inc.*

Human Genome Sciences Inc. (HGSI)

Research collaboration/use of Praecis' screening technology for two HGS targets to identify small-molecule drugs for metabolic disorders and infectious diseases

ND (2/00)

Protein Design Labs Inc. (PDLI)

Celltech Chiroscience plc (UK; LSE:CTH)

Cross-license agreement/intellectual property in the field of humanized monoclonal antibodies

Celltech will pay a $3M up-front fee for a nonexclusive worldwide license to PDL's antibody humanization patents for up to three Celltech antibodies; PDL will pay Celltech an up-front fee for non-exclusive worldwide rights to Celltech's antibody humanization patent for up to three PDL antibodies; upon exercise of a license for a particular antibody, the licensee will pay an additional fee; each company will pay royalties to the other based on sales of licensed antibodies (1/00)

Protein Pathways Inc.*

UroGenesys Inc.*

Research collaboration/application of Protein Pathways' bioinformatics technologies to UroGenesys' database of cancer antigens

Companies expect the combination of technologies to uncover functional information that will guide development of UroGenesys' antigens, as well as identify new candidates for cancer therapy (2/00)

Ribozyme Pharmaceuticals Inc. (RZYM)

Elan Corp. plc (Ireland; NYSE: ELN)

Joint venture/RPI's Herzyme ribozyme against human epidermal growth factor receptor-2 (HER-2) for treatment of breast and other cancers using Elan'sMedipad drug delivery system

Under terms of transaction (preliminary announcement made 12/99), companies created a joint venture called Medizyme Pharmaceuticals Ltd. to develop and commercialize the product, licensed from RPI, which has contributed $12M in initial funding in exchange for 80.1% of Medizyme's capital stock; Medizyme will receive additional funding from RPI's sale to Elan of convertible preferred stock; Medizyme paid RPI a license fee; Elan purchased $5M of RPI common stock and will purchase another $5M in 15 months as a milestone payment; Elan also received warrants to purchase common stock and has the right to exchange its RPI preferred stock for additional Medizyme capital stock or RPI common stock (1/00)

Scriptgen Pharmaceuticals Inc.*

3-Dimensional Pharmaceuticals Inc.*

Settlement of intellectual property dispute/Scriptgen's ATLAS (Any Target Ligand Affinity Screen) and 3DP's ThermoFluor assay technology

3DP will purchase a limited non-exclusive worldwide license to current and pending patents related to Scriptgen's ATLAS; 3DP will grant Scriptgen a limited, nonexclusive worldwide license to pending patents relating to ThermoFluor; both companies can use their respective assay technologies for identification of drugs in a broad range of therapeutic areas, with the exception of anti-infectives, in which Scriptgen holds a preferential position (3/00)

Shaman Pharmaceuticals Inc. (OTC BB:SHMN)

Metabolex Inc.*

License agreement/Shaman's diabetes drug discovery program, principally focused on orally available plant-derived compounds for Type II diabetes; includes library of more than 300 compounds and extracts

Metabolex acquired materials and exclusive licenses to Shaman's diabetes drug discovery program for use within specific territories; Shaman retains all rights to lead diabetes compound, Masaprocol (1/00)

Symyx Technologies Inc. (SMMX)

PE Biosystems (NYSE:PEB)

Development collaboration/development of Symyx's polymer synthesis materials and methods for use in DNA analysis

Companies will jointly design polymers, as well as methods and instrumentation for screening those polymers; Symyx will make and screen the polymers for use in nucleic acid separations; PE will develop and commercialize products; under the two-year agreement, Symyx will receive payments for development funding and late-stage royalties on resulting products; in addition, Symyx will receive a payment for transfer of existing development compounds (1/00)

Techniclone Inc. (TCLN)

SuperGen Inc. (SUPG)

License agreement/use of Techniclone's Vascular Targeting Agent to develop cancer therapeutics

Techniclone will receive an up-front payment, milestones and royalties on productsthat emerge (1/00)

Techniclone Inc. (TCLN)


Joint venture/development of cancer therapeutics combining Techniclone's vascular targeting agents and Oxigene's tubulinbinding compounds

Techniclone will receive an up-front licensing fee and milestone payment; OXiGENE will fund development expenses, and the companies will share royalties and certain fees generated by the joint venture; Techniclone will supply its intellectual property and the expertise of VTA's inventor, along with the most promising lead candidates (3/00)

TranXenoGen Inc.*

US Transgenics Inc.*

Joint venture and research collaboration/development of recombinant human serum albumin (HAS) under JV structure and research collaboration to develop other proteins in the albumin fraction of chicken eggs using TranXenoGen's transgenic chicken technology

TranXenoGene will house initial HSA project at its facilities; US Transgenics will provide protein chemistry technology and access to product markets (1/00)

Trega Biosciences Inc. (TRGA)

Discovery Technologies Inc. (subsidiary of Discovery Partners InternationalInc.*)

Technology alliance/use of Trega's Chem.Folio chemistry libraries by Discovery for client screening using an ultra-high-throughput screening system

Trega receives an up-front payment plus additional fees on compounds accessed by Discovery customers for a period of two years; Discovery's use of the libraries is non-exclusive (2/00)

Trega Biosciences Inc. (TRGA)

Evotec Biosystems AG (Germany; Neuer Markt:EVT)

License agreement, research collaboration and purchase agreement/development of high-throughput ADME (absorption, distribution, metabolism and excretion) assays for use in drug discovery lead optimization; license of Trega's IDEA predictive model; purchase of Trega's Chem.Folio chemistry libraries

Evotec will have an exclusive license to all developed ADME assays, while Trega will be entitled to royalties on drug discovery collaboration revenues of assays offered to third parties by Evotec; Trega also will own the data generated on a selected set of compounds; Evotec gains a license to IDEA; Chem.Folio library compounds will be screened through the new assays and the data will be used to enhance IDEA; Evotec will purchase certain amounts of all compounds in Trega's Chem.Folio library, and will receive associated information; Evotec will use the compounds for internal drug discovery and make them accessible to screening customers for a fee that includes a payment to Trega (1/00)

Tripos Inc. (TRPS)

Lion Bioscience AG* (Germany)

Research collaboration/integration of Lion's bioinformatics and Tripos' chemoinformatics expertise to develop a unified platform

Companies formalized alliance that has grown out of 18 months of unannounced collaborative efforts; Lion agreed to purchase 409,091 shares of convertible preferred stock from Tripos for $22 per share, or $9M, giving Lion an 11% stake in Tripos (2/00)

Vical Inc. (VICL)

Vascular Genetics Inc.*

License agreement/use of Vical's naked DNA delivery technology for VGI's vascular endothelial growth factor-2 (in clinical trials for cardiovascular disorders)

VGI receives an exclusive, royalty-bearing license; in exchange, Vical receives a minority equity interest in VGI (2/00)

Vion Pharmaceuticals Inc. (VION)

Achillion Pharmaceuticals Inc.*

License agreement/Vion's nucleoside analogue B-L-Fd4C for treating hepatitis B virus infection and HIV

Achillion will fund development, in return for providing Vion with milestones, downstream royalties and an equity position (2/00)

Viragen Inc. (OTC BB: VRGN)

CryoLife Inc. (NYSE:CRY)

Research collaboration/use of CryoLife's light activation technology with Viragen anticancer proteins delivered to tumors by monoclonal antibodies; the proteins are designed to be activated and separated from the antibodies upon application of light

Companies signed a feasibility agreement (3/00)

Xenometrix Inc. (OTC BB: XENO)

Genometrix Inc.*

License agreement/Xenometrix's collection of gene expression profiles utilizing all platforms, including microarrays

Genometrix receives a non-exclusive license (3/00)


# This chart does not include any agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX =American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange